

57

(12) UK Patent Application (19) GB (11) 2 246 779 (13) A

(43) Date of A publication 12.02.1992

(21) Application No 9017083.8

(22) Date of filing 03.08.1990

(71) Applicant
Dette Biotechnology Limited
(Incorporated in the United Kingdom)

Castle Court, Castle Boulevard, Nottingham, NG7 1FD,
United Kingdom

(72) Inventors
David James Bailance
Michael George Courtney

(74) Agent and/or Address for Service
Eric Potter & Clarkson
St Mary's Court, St Mary's Gate, Nottingham, NG1 1LE,
United Kingdom

(51) INT CL⁶

C07K 15/00, A61K 37/02, C12N 15/15 15/58 15/62 //
(C07K 15/00 C12R 1:19)

(52) UK CL (Edition K)

C3H HB7M HB7P HHX2 H530 H650 H651 H652
H654 H655 H660 H675 H684 H687 H690
C6Y YG12 YG13 YG16 Y115 Y125 Y327 Y330
Y332 Y333 Y336 Y337 Y338 Y339 Y340 Y341 Y342
Y343
U1S S1313

(56) Documents cited

EP 0383599 A2 EP 0122132 A2 EP 0044167 A2
WO 90/12091 A1
PROC. NATL. ACAD. SCLUSA, Vol. 87, pages 2230-
2234, 1990.
BLOOD, Vol. 74, 1988, pages 1396-1402.
J. IMMUNOL., Vol. 143, 1989, pages 2634-2639.
CELL, Vol. 52, No. 3, 1988, pages 321-328.
J. BIOL. CHEM., Vol. 262, No. 10, 1987, pages 4437-
4440.

(58) Field of search

UK CL (Edition K) C3H HB7M HB7P HHX2
INT CL⁶ C07K, C12N
Online databases: WPI; DIALOG (BIOTECH)

(54) Antitumour molecules

(57) A molecule comprises a first region which binds to a tumour (preferably the receptor for uPA (urokinase-type plasminogen activator)) and a second region which inhibits a tumour-associated protease, for example uPA. The first and second regions may be respective antibodies or parts thereof specific for appropriate parts of uPAR (urokinase-type plasminogen activator receptor) and uPA. Preferably, the first region is a uPAR-binding part of uPA, e.g. the 12-32 region thereof, and the second region is PAI-2 or a uPA-inhibiting analogue or part thereof. The two regions may be combined by chemically linking them or by expressing them as a single polypeptide in a suitably transformed host.

At least one drawing originally filed was informal and the print reproduced here is taken from a later filed formal copy.

ATTORNEY DOCKET NUMBER: 9471-019-999
SERIAL NUMBER: 10/687,554
REFERENCE: B02




Fig. 1

2/16
AAGCTTGTCTG ACGGATCCAA AAAG ATG GAA GAT CTT
53

Met Glu Asp Leu
1

TGT GTG GCA AAC ACA CTC TTT GCC CTC AAT TTA TTC AAG CAT CTG GCA
101
Cys Val Ala Asn Thr Leu Phe Ala Leu Asn Leu Phe Lys His Leu Ala
5 10 15 20

AAA GCA AGC CCC ACC CAG AAC CTC TTC CTC TCC CCA TGG AGC ATC TCG
149
Lys Ala Ser Pro Thr Gln Asn Leu Phe Leu Ser Pro Trp Ser Ile Ser
25 30 35

TCC ACC ATG GCC ATG GTC TAC ATG GGC TCC AGG GGC AGC ACC GAA GAC
197
Ser Thr Met Ala Met Val Tyr Met Gly Ser Arg Gly Ser Thr Glu Asp
40 45 50

CAG ATG GCC AAG GTG CTT CAG TTT AAT GAA GTG GGA GCC AAT GCA GTT
245
Gln Met Ala Lys Val Leu Gln Phe Asn Glu Val Gly Ala Asn Ala Val
55 60 65

ACC CCC ATG ACT CCA GAG AAC TTT ACC AGC TGT GGG TTC ATG CAG CAG
293
Thr Pro Met Thr Pro Glu Asn Phe Thr Ser Cys Gly Phe Met Gln Gln
70 75 80

ATC CAG AAG GGT AGT TAT CCT GAT GCG ATT TTG CAG GCA CAA GCT GCA
341
Ile Gln Lys Gly Ser Tyr Pro Asp Ala Ile Leu Gln Ala Gln Ala Ala
85 90 95 100

GAT AAA ATC CAT TCA TCC TTC CGC TCT CTC AGC TCT GCA ATC AAT GCA
389
Asp Lys Ile His Ser Ser Phe Arg Ser Leu Ser Ser Ala Ile Asn Ala
105 110 115

Figure 2 (first sheet)

3/16

TCC ACA GGG AAT TAT TTA CTG GAA AGT GTC AAT AAG CTG TTT GGT GAG
 437
 Ser Thr Gly Asn Tyr Leu Leu Glu Ser Val Asn Lys Leu Phe Gly Glu

120

125

130

AAG TCT GCG AGC TTC CGG GAA GAA TAT ATT CGA CTC TGT CAG AAA TAT
 485
 Lys Ser Ala Ser Phe Arg Glu Glu Tyr Ile Arg Leu Cys Gln Lys Tyr

135

140

145

TAC TCC TCA GAA CCC CAG GCA GTA GAC TTC CTA GAA TGT GCA GAA GAA
 533
 Tyr Ser Ser Glu Pro Gln Ala Val Asp Phe Leu Glu Cys Ala Glu Glu

150

155

160

GCT AGA AAA AAG ATT AAT TCC TGG GTC AAG ACT CAA ACC AAA GGC AAA
 581
 Ala Arg Lys Lys Ile Asn Ser Trp Val Lys Thr Gln Thr Lys Gly Lys

165

170

175

180

ATC CCA AAC TTG TTA CCT GAA GGT TCT GTA GAT GGG GAT ACC AGG ATG
 629
 Ile Pro Asn Leu Leu Pro Glu Gly Ser Val Asp Gly Asp Thr Arg Met

185

190

195

GTC CTG GTG AAT GCT GTC TAC TTC AAA GGA AAG TGG AAA ACT CCA TTT
 677
 Val Leu Val Asn Ala Val Tyr Phe Lys Gly Lys Trp Lys Thr Pro Phe

200

205

210

GAG AAG AAA CTA AAT GGG CTT TAT CCT TTC CGT GTA AAC TCG GCT CAG
 725
 Glu Lys Lys Leu Asn Gly Leu Tyr Pro Phe Arg Val Asn Ser Ala Gln

215

220

225

CGC ACA CCT GTA CAG ATG ATG TAC TTG CGT GAA AAG CTA AAC ATT GGA
 773
 Arg Thr Pro Val Gln Met Met Tyr Leu Arg Glu Lys Leu Asn Ile Gly

230

235

240

Figure 2 (second sheet)

4/16

TAC ATA GAA GAC CTA AAG GCT CAG ATT CTA GAA CTC CCA TAT GCT GGA
821
Tyr Ile Glu Asp Leu Lys Ala Gln Ile Leu Glu Leu Pro Tyr Ala Gly

245 250 255 260

GAT GTT AGC ATG TTC TTG TTG CTT CCA GAT GAA ATT GCC GAT GTG TCC
869
Asp Val Ser Met Phe Leu Leu Leu Pro Asp Glu Ile Ala Asp Val Ser

265 270 275

ACT GGC TTG GAG CTG CTG GAA AGT GAA ATA ACC TAT GAC AAA CTC AAC
917
Thr Gly Leu Glu Leu Leu Glu Ser Glu Ile Thr Tyr Asp Lys Leu Asn

280 285 290

AAG TGG ACC AGC AAA GAC AAA ATG GCT GAA GAT GAA GTT GAG GTA TAC
965
Lys Trp Thr Ser Lys Asp Lys Met Ala Glu Asp Glu Val Glu Val Tyr

295 300 305

ATA CCC CAG TTC AAA TTA GAA GAG CAT TAT GAA CTC AGA TCC ATT CTG
1013
Ile Pro Gln Phe Lys Leu Glu Glu His Tyr Glu Leu Arg Ser Ile Leu

310 315 320

AGA AGC ATG GGC ATG GAG GAC GCC TTC AAC AAG GGA CGG GCC AAT TTC
1061
Arg Ser Met Gly Met Glu Asp Ala Phe Asn Lys Gly Arg Ala Asn Phe

325 330 335 340

TCA GGG ATG TCG GAG AGG AAT GAC CTG TTT CTT TCT GAA GTG TTC CAC
1109
Ser Gly Met Ser Glu Arg Asn Asp Leu Phe Leu Ser Glu Val Phe His

345 350 355

CAA GCC ATG GTG GAT GTG AAT GAG GAG GGC ACT GAA GCA GCC GCT GGC
1157
Gln Ala Met Val Asp Val Asn Glu Glu Gly Thr Glu Ala Ala Ala Gly

360 365 370

Figure 2 (third sheet)

5/16

ACA GGA GGT GTT ATG ACA GGG AGA ACT GGA CAT GGA GGC CCA CAG TTT
1205
Thr Gly Gly Val Met Thr Gly Arg Thr Gly His Gly Gly Pro Gln Phe
375 380 385

GTG GCA GAT CAT CCT TTT CTT TTT CTT ATT ATG CAT AAG ATA ACC AAC
1253
Val Ala Asp His Pro Phe Leu Phe Leu Ile Met His Lys Ile Thr Asn
390 395 400

TGC ATT TTA TTT TTC GGC AGA TTT TCC TCA CCC TAAGTCGACAA
1306
Cys Ile Leu Phe Phe Gly Arg Phe Ser Ser Pro ter
405 410 415

GCTTGATCC

Figure 2 (fourth sheet)

HindIII

aagcttactgctgacctttgccttggtccttgacttgctcgttgcggnnaccattaa
ttcgaatgacgactggaaacggaaccaggaacatgaacagagctaacgacnntggtaatt

cggttttttgttcttacttaatctttttttcccgacgacgcaaaatgtcagaaaagata
gccaaaaaacaagaatgaattagaaaaaaaagggtgctgctgctgttttacagtcttttctat

taaanagagcaacgtttcctgctacatgaaacacgctggcatatagaagaacttcaacga
attntctcgttgcaaaggacgatgtactttgtgacgacctatcttcttgaagttgct

gcgaggctctctgaacaatctgctaactgtgcaagtaagggttctcgtgacagttcacccg
cgctccgagagacttgtagacgattagcacgttcattccaagagcactgtcaagtggc

tgtataaacaagnnnaaacagataaacagtcagatatgottaatttttaactgtaggctg
acataatttgctcnnntttgtctatttgctcagctctatacgaattaaaaattgacatccgac

tgcgacatgccattttatgcggctcacttctaacaaaagtgacctgacgcacaagcaa
acggctgtacggtaaaatacgcgcgagtgaagattgttttactggtagctgctgttctgt

gcaaacagccaagtaaggaagcagacagcttcacagcacacacacaccggttggtgacgaa
cgtttgctcgttcattccttcgtctgtcgaagtgtcgtgtgtgtgtgtggcaacacatgctt

SnaBI

aatcctctgcagaagagtgtatatgccactcatccacacttccgcagcgcagtaacgtaat
ttaggagacgtcttctcacatatacgggtgagtaggtgtgaaggcgtcgcgtcatgcatta

gcgggtatcgtgaaagcgaaaaaaaaactaacagtagataagacagatagacagatagaga
cgccatagcactttcgtcttttttttgattgtcatctattctgtctatctgtctatctct

tggacgagaaaaacaggggggggagaaaaaggggaaaaagagaaggaaagaaagactcatctat
acctgctcttttgcctccctctctttcccttttctcttctcttcttctgtagtagata

cgcagataagacaatcaaccctcatggcgctccaaccaccatccgcaactagggaccaag
gcgtctattctgttagttgggagtagccgcggaggttggtggtaggcgtgatccctgggtc

cgctcgacccgttagcaacgcttgactcacaaccaactgcgggtgaaagagcttggtgc
gcgagcgtggcaatcgttgcaactgagtggttggttgacggcgactttctcgaacacg

aatgggagtgccaattcaaaggagcogaatacgtctgctcgcttttaagaggctttttg
ttaccctcacggttaagtttctcgtgcttatgcagacgagcggaaaattctccgaaaaac

aacactgcattgcacccgacaaatcagccactaactacgaggtcacggacacatatacca
ttgtgacgtaacgtgggctgtttagtcggtgattgatgctccagtgcctgtgtatatggt

atagttaaaaattacatatactctatatagcacagtagtgatgataaaaaattttgc
tatcaatttttaattgtatatgagatatatcgtgtcatcacactatttttttaaaacg

caagacttttttaaaactgcacccgacagatcaggtctgtgcctactatgcacttatgcc
gttctgaaaaaatttgacgtgggctgtctagtccagacacggatgatacgtgaatacggg

gggggtcccgggaggagaaaaaacgagggtgggaaatgtccgtggactttaaacgctccg
ccccaggggcctcctcttttttgcctccgacacctttacaggcacctgaaatttgcgaggc

Figure 3a

ggttagcagagtagcagggctttcggctttggaaattaggtgacttggtgaaaaagcaa
ccaatcgtctcatcgtcccgaagccgaaacctttaatccactgaacaacttttcggt

aatttgggctcagtaatgccactgcagtggcttatcacgccaggactgcgggagtgggcg
ttaaaccgagtcattacgggtgacgtcaccgaatagtgcggtcctgacgccctcaccgcc

gggcaaacacaccgcgataaagagcgcgatgaatataaaagggggccaatgttacgtcc
cccgtttggtggtggcgctatctcgcgctacttatattttcccccggttacaatgcagg

cgttatattggagttcttccatacaaacttaagagtcgaattagcttcatcgccaataa
gcaatataacctcaagaagggtatggttgaaattctcaggttaatcgaagtagcggttatt

aaaaacaaactaaacctaatcttaacaagcaaagatgaagttagaaaatactctatttac
tttttggttgatttgattaagattgttcggttctacttcaatcttttatgagataaatg

actcggtgccctagggagcatctctgctgctttggtcatcccaaatcttgaaaatgccgc
tgagccacgggatccctcgtagagacgacgaaaccagtaggggttagaacttttacggcg

EcoRI

cgaccaccacgaactgattaacaaggaagatcaccacgagagaccagaaaagtgggaattc
gctgggtggtgcttgactaattgttccttctagtgggtgctctctgggtcttttcaccttaag

Figure 3b




FIGURE 4




FIGURE 5

10/16




FIGURE 6




FIGURE 7




FIGURE 8




Fig. 9




Fig. 10

15/16




Fig. 11

DNA sequence in pDBUA1.

Alpha-1-antitrypsin

```

Asp Pro Gln Gln Lys Thr Asp Thr Ser His His Asp Gln Asp His
GAT CCC CAG CAG AAG ACA GAT ACA Gln TTC CAC CAT GAT CAG GAT CAC
CCA ACC TTC Ala Gln Pro Asn Lys Thr Ser Phe Ala Gln His Asp Gln Asp
Gln Leu Ala His CAC AAG Gln Ser Asn ACC Thr Leu Phe TTC GCC Phe TTT
CAG CTG GCA Phe Ala Met CAC TCC Ser Leu ACC GGT Gln GAG GCT Ala ACT
Thr Ala TTT GCA Asn Phe Arg CCG Thr Asn CAG Gln GAG GCT Ala ACT
Glu GGC Gln AAT CTC Leu CAC TCC Ser Asn CAG Gln GAG GCT Ala ACT
Gln GAA Gln CTC Leu CAC TCC Ser Asn CAG Gln GAG GCT Ala ACT
Asn GGC Gln CTC Leu CAC TCC Ser Asn CAG Gln GAG GCT Ala ACT
Lys Lys Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
AAA AAG Lys TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
Lys Lys Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
Val Lys Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
GTC AAG Lys TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
Gly Lys Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
GGC AAA Lys TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
ASP CAG Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
Gln CAC Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
CAG Ala Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
Thr CAC Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
ACC GGC Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
His CAC Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
CAT TTA Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
Leu GGC Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
CTG GGC Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
Ala GGC Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
GCA CCC Thr Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
Gly GGC Thr Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
GGG ACT Thr Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
Glu GGC Thr Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
GAG Val Thr Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
Pro CTC Thr Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe
CCC Gln TTT GCA Gln Gln GAG GGT Val Phe Gln GAG GGT Val Phe

```

Fig. 12

THERAPEUTICALLY USEFUL MOLECULES

The process of activation of the zymogen plasminogen to the broad spectrum serine protease, plasmin, is mediated by specific plasminogen activators: tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). tPA is primarily responsible for the generation of plasmin in fibrinolysis and its activity is stimulated when bound to fibrin. In humans, and many other species, uPA is important in generating proteolytic activity responsible for extracellular matrix and basement membrane degradation associated with tissue remodelling. Such processes are involved in growth and spread of tumour cells, mammary gland involution, ovulation, embryo development, development of the nervous system, in the normal inflammatory response and in a number of inflammatory diseases (Danø *et al*, 1985). Elevated levels of uPA have been found in malignant tissue and there is believed to be a general correlation between the amount of uPA and the invasiveness of the tumour. Studies of experimental Lewis lung tumours revealed concentration of uPA at the invasive edge of the tumours. In addition, anti-catalytic antibodies to uPA inhibited the establishment of tumour cells after i.v. injection into mice and inhibited metastasis in chick embryos. The proteolytic activity released by uPA is localized by the binding of plasminogen, plasmin and uPA to specific cell surface receptors (Vassalli *et al*. 1985; Miles and Plow, 1988) and the importance of receptor-bound uPA in tissue invasion has been demonstrated (Ossowski,

1988). The receptor-binding region has been localized to the growth factor domain of the uPA molecule in the region of amino acids 12-32 of mature uPA since peptides corresponding to this sequence are able to block the uPA receptor interaction by competition (Appella et al, 1987).

The apparent central role of uPA in malignant disease indicates that inhibition of the activity of uPA might modify the course of the disease. Of the natural inhibitors of uPA, only plasminogen activator inhibitor 1 (PAI-1) and plasminogen activator inhibitor 2 (PAI-2) are sufficiently active and specific enough to be considered (Sprengers and Kluft, 1987). Although PAI-1 is a faster inhibitor of uPA than PAI-2 it is also a very effective inhibitor of tPA and administration of this protein would be likely to compromise fibrinolysis. PAI-2, on the other hand, is a slower inhibitor of tPA and is reported to be inactive against the physiologically important fibrin-stimulated tPA. PAI-2 has been shown to inhibit receptor-bound uPA (Kirchheimer and Remold, 1989a; Pöllänen et al 1990) and uPA-dependent tissue invasion (Kirchheimer and Remold, 1989b) and thus represents a potentially useful anti-tumour or anti-metastatic agent. Natural sources of PAI-2 yield very small quantities of the protein but EP-A-238 275 discloses the production of recombinant PAI-2 in *E. coli*. Our co-pending application GB8918191.1 discloses the advantageous production of recombinant PAI-2 in *Saccharomyces cerevisiae*.

Fusions of PAI-2 and other polypeptides are described in EP-A-238 275 (page 30) but only in the context of obtaining secretion of the PAI-2 from a transformed cell producing it or in the context of detecting PAI-2 production as a β -galactosidase fusion.

WO 88/08451 discloses uPA-tPA fusions, but the portion of uPA which is used is the B chain and the intention is to retain the activities of both tPA and uPA. As is described below, the uPA-derived portion (if present) of the molecules of the present invention preferably has substantially no uPA-like amidolytic or proteolytic activity.

One aspect of the invention provides a molecule comprising a first region which binds to a tumour cell and a second region which inhibits a tumour-associated protease.

The specific tumour-binding may be enabled by the existence on the tumour of structures unique to the tumour, for example tumour-specific antigens such as CEA (carcino-embryonic antigen), pan carcinoma antigen, placental alkaline antigen or polymorphic epithelial mucin antigen. Alternatively, the specificity may arise from the existence of a higher level or density on the tumour cell surface of a structure which is found on normal cells; the receptor for uPA (uPAR) is an example of such a structure.

The tumour-binding region is preferably an entity which will bind to the receptor for uPA (uPAR), as is described in more detail below. Alternatively, it may be any other entity which binds preferentially to a tumour cell, for example the plasminogen-receptor-binding domain of plasminogen as disclosed in Miles *et al* 1988.

The tumour-associated protease is preferably urokinase-type plasminogen activator (uPA) as is described in more detail below. However, it could be any other protease of which high local levels are associated with tumours, or at least tumours of a given kind. Preferably the protease is one that can be activated or converted from a pro-enzyme or zymogen form by uPA or receptor-bound uPA to generate localised proteolytic activity. The inhibitor region in the molecule of the invention may be an inhibitor of plasmin such as the Pittsburgh variant of α_1 -antitrypsin, an α_1 AT variant having lysine at the P_1 position, α_2 -antiplasmin, α_2 -macroglobulin, aprotinin or any other inhibitor with plasmin inhibitory activity, or it may be an inhibitor of a collagenase such as tissue inhibitor of metallo-proteinases (TIMP) or the related TIMP2. In all of these cases an inhibitory portion of the protease inhibitor may be used instead of the whole molecule.

The molecule thus provides for the targeting of the protease inhibiting region to the tumour cell.

The protease the activity of which is inhibited may be free or bound to its receptor.

The first region is preferably a peptide sequence corresponding to a receptor-binding region of the protease. Thus, the first region may comprise amino acids 1-32 of uPA or a variant or fragment thereof. By "variant" we mean a region with one or more minor alterations to the amino acid sequence thereof which region is nevertheless recognisably similar to the said 1-32 region and which still binds to the uPA-binding site on the uPAR. Incidentally, although the region is generally "EGF-like", EGF itself does not bind to the said site. By "fragment" we mean smaller sequences (preferably at least 10, 15, 19 or 20 amino acids long) which still bind to the binding site of the receptor, for example the 20-30 region of uPA. "Variants" of "fragments" may also be used. The receptor-binding region of the protease may, in the molecule of the invention, be accompanied by other parts of the protease or a pro-form of the protease or a mutant thereof. Such parts or mutants should have at least 50% homology, preferably 60%, 70%, 80%, 90% or 95% homology with the protease (or, in the case of parts, with the corresponding region of the protease) in order to be regarded as parts or mutants thereof. They should, however, at least when present in the molecule of the invention, not have any undesirable level of protease-like proteolytic activity, since otherwise the point of the invention would be lost. Preferably, the protease-derived

part of the molecule of the invention, at least when present in the said molecule, has substantially no protease-like proteolytic activity. In the case of uPA, it may be possible to achieve this simply by using a pro-uPA mutant in which Lys¹⁵⁸ has been altered, for example to Gln or Gly, to prevent cleavage by plasmin. The 12-19 and 31-32 residue regions adjacent the 20-30 binding region of uPA seem to help the binding region to bind optimally and are preferably present, or functionally equivalent flanking regions are present.

The first region may alternatively be a monoclonal antibody or part thereof or a genetically engineered counterpart thereof which binds to the protease receptor, preferably uPAR. Preferably, it binds to the protease-binding site of the receptor or it binds to an area of the receptor which is sufficiently close to the said binding site for the bulk of the molecule as a whole to block binding of the protease to the receptor. In this way, not only is the protease-inhibiting region targeted to the receptor, but the protease-binding site of the receptor is blocked, which will prevent binding of the protease to that receptor and thus may further help to prevent the protease from activating its substrate.

In other embodiments, the first region consists of any peptide which will bind to the protease-binding site, or sufficiently close to it to block it, and need not be homologous with any part of the protease.

The second region may be any compound which inhibits the action of the protease (preferably uPA). Such a compound may be an antibody directed against the enzymatically active site of the protease, or against such a part of the protease molecule as to block access of the substrate to the active site or against any other part of the protease such that binding of the antibody to the said part prevents or at least reduces the activation by the protease of its substrate.

In a particularly preferred embodiment, however, the second region is PAI-2 or part thereof or a mutant PAI-2 or part thereof. Preferably, the mutant or part of PAI-2 retains a useful level of the uPA-inhibiting activity of PAI-2. Fusions of the uPAR-binding domain of uPA and PAI-2 or a part or mutant thereof (hereinafter called "uPA-PAI-2 fusions") may exhibit the following properties:

1. binding free uPAR (i.e. uPAR unoccupied by uPA) via the growth factor domain, thereby blocking binding by uPA to uPAR,

2. in solution, inhibiting free or receptor-bound uPA, and
3. when receptor-bound, inhibiting receptor-bound uPA.

The molecule should be stable *in vivo*. By "stable *in vivo*", we mean that the molecule is sufficiently stable when administered parenterally, preferably intravenously, to allow useful quantities of it to reach a tumour and bind to the receptors on the tumour cells. In practice, a molecule with a half-life in circulating human blood of 30 minutes or longer is considered to be stable. Preferably, the half-life is at least 1 hour, 24 hours, 3 days or more.

The molecules of the invention may be dissolved in suitable delivery vehicles and administered to patients to inhibit or prevent the growth or spread of an actual or suspected tumour. The patient is preferably a human but may be another animal, preferably a mammal, such as a pet (dogs, cats, etc) or an economically important animal (sheep, cattle, pigs, fowl, horses, etc). In these days of transgenic animals producing valuable pharmaceuticals, it may be increasingly worthwhile to apply sophisticated human medicine to such animals. In the case of administration to animals, the tumour-binding domain is modified for optimal binding to the animal receptor and ideally is the sequence of the said domain of the protease of that animal. The molecules are preferably administered parenterally,

for example intravenously, intramuscularly or subcutaneously, by injection or infusion. Clinically qualified people will be able to determine suitable dosages, delivery vehicles and administrative routes.

The molecules of the invention may be produced by chemically linking the said first and second regions by methods known to those in the art of protein chemistry, for example using the methods of O'Sullivan *et al* (1979) and bifunctional linking reagents such as m-maleimido-benzoyl-N-hydroxy-succinimide ester. However, it is preferred for the molecules to be produced by expression of a recombinant DNA sequence in a suitable host transformed therewith. Such hosts are legion and include *E. coli*, *B. subtilis*, *Aspergillus* and other filamentous fungi, and yeasts.

Exemplary genera of yeast contemplated to be useful in the practice of the present invention are *Pichia*, *Saccharomyces*, *Kluyveromyces*, *Candida*, *Torulopsis*, *Hansenula*, *Schizosaccharomyces*, *Citeromyces*, *Pachysolen*, *Debaromyces*, *Metschunikowia*, *Rhodospiridium*, *Leucosporidium*, *Botryosascus*, *Sporidiobolus*, *Endomycopsis*, and the like. Preferred genera are those selected from the group consisting of *Pichia*, *Saccharomyces*, *Kluyveromyces*, *Yarrowia* and *Hansenula*, because

the ability to manipulate the DNA of these yeasts has, at present, been more highly developed than for the other genera mentioned above.

Examples of *Saccharomyces* are *Saccharomyces cerevisiae*, *Saccharomyces italicus* and *Saccharomyces rouxii*.

Examples of *Kluyveromyces* are *Kluyveromyces fragilis* and *Kluyveromyces lactis*.

Examples of *Hansenula* are *Hansenula polymorpha*, *Hansenula anomala* and *Hansenula capsulata*.

Yarrowia lipolytica is an example of a suitable *Yarrowia* species.

Yeast cells can be transformed by: (a) digestion of the cell walls to produce spheroplasts; (b) mixing the spheroplasts with transforming DNA (derived from a variety of sources and containing both native and non-native DNA sequences); and (c) regenerating the transformed cells. The regenerated cells are then screened for the incorporation of the transforming DNA.

It has been demonstrated that yeast cells of the genera *Pichia*, *Saccharomyces*, *Kluyveromyces*, *Yarrowia* and *Hansenula* can be transformed by enzymatic digestion of the cell walls to

give spheroplasts; the spheroplasts are then mixed with the transforming DNA and incubated in the presence of calcium ions and polyethylene glycol, then transformed spheroplasts are regenerated in regeneration medium.

Methods for the transformation of *S. cerevisiae* are taught generally in EP 251 744, EP 258 067 and WO 90/01063, all of which are incorporated herein by reference.

In the case of PAI-2-based fusions, the protein is preferably produced as a soluble intracellular protein.

Suitable promoters for *S. cerevisiae* include those associated with the *PGK1* gene, *GAL1* or *GAL10* genes, *CYC1*, *PHO5*, *TRP1*, *ADH1*, *ADH2*, the genes for glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, triose phosphate isomerase, phosphoglucose isomerase, glucokinase, α -mating factor pheromone, a-mating factor pheromone, the *PRB1* promoter, the *GUT2* promoter, and hybrid promoters involving hybrids of parts of 5' regulatory regions with parts of 5' regulatory regions of other promoters or with upstream activation sites (e.g. the promoter of EPA-258067). The preferred promoter is the *PRB1* promoter.

The transcription termination signal is preferably the 3' flanking sequence of a eukaryotic gene which contains proper signals for transcription termination and polyadenylation. Suitable 3' flanking sequences may, for example, be those of the gene naturally linked to the expression control sequence used, i.e. may correspond to the promoter. Alternatively, they may be different in which case the termination signal of the *S. cerevisiae* ADHI gene is preferred.

Suitable secretion leader sequences, if the molecule is to be secreted from the host, include mammalian leader sequences, such as the HSA and pro-uPA leader sequences, *S. cerevisiae* leader sequences such as the α -mating factor pheromone pre- and prepro- sequence, the invertase (*SUC2*) leader sequence, the *PHO5* leader sequence, or hybrid leader sequences such as the leader sequence of WO 90/01063.

The amino acid sequence of the N-terminal portion of uPA encompassing the growth factor domain is as follows:

10	20	30
S N E L H Q V P S N C D C L N G G T C V S N K Y F S N I H W C N		
40	50	
C P K K F G G Q H C E I D K S K T C		

The sequence of residues 20-30 is responsible for the specificity of binding to the receptor and this sequence may represent the minimum requirement for binding to the receptor. Sequences adjacent to this region provide the proper conformation for optimum binding but may be substituted by a functionally equivalent structure. The uPA sequence incorporated into the fusion molecules preferably includes residues 12-32 and in the preferred embodiment includes residues 1-47 to ensure optimum binding to uPAR. It is not necessary for the first region of the molecule of the invention to be at or adjacent the N-terminal of the molecule. The second region can be N-terminal to the first region.

DNA sequences for expression of the molecules of the invention may be prepared by known techniques, for example by fusing cDNA fragments prepared from mRNAs corresponding respectively to the receptor-binding region of the protease and to a protease inhibitor or a part thereof.

Monoclonal antibodies may be prepared generally by the techniques of Zola (1988) which is incorporated herein by reference. Useful antigens for preparing either monoclonal or polyclonal antibodies are (for the second region) uPA, low molecular weight uPA or the heavy (B) chain of uPA, and (for the first region) uPAR or peptides based on the uPA-binding domain thereof. Antibody fragments such as F_{ab} fragments, may be

prepared therefrom in known ways. The antibodies may be humanized in known ways. Antibody-like molecules may be prepared using the recombinant DNA techniques of WO 84/03712.

The art of "antibody engineering" is advancing rapidly, as is described in Tan & Morrison (1988), Williams (1988) and Neuberger et al (1988) (all of which are incorporated herein by reference), and is well suited to preparing the first or second regions of the molecules of the invention or the whole molecule itself. Thus, bispecific antibodies, specific for an appropriate receptor and an appropriate site on the protease, may be made by any of the methods described by Williams (1988). Such molecules will block the protease-binding site of the receptor and also inhibit the protease. The antibody may alternatively be bispecific for the receptor and the protease inhibitor (or a mutant or fragment thereof) so that the antibody acts to bind the inhibitor to the receptor. The combination of the antibody bound to the inhibitor (or a mutant or fragment thereof) thus constitutes a molecule of the invention, whereas the antibody itself constitutes a precursor thereof, forming a separate aspect of the invention. The antibody specific for the receptor and the inhibitor may be combined with the inhibitor before being administered or may be co-administered therewith. By "co-administered", we do not necessarily mean that the antibody and

the inhibitor must be administered simultaneously; it is sufficient for them to combine in a therapeutically useful way in the body.

Chimaeric antibodies, where the F_C region is a human immunoglobulin or part thereof, may be desirable for long term treatment, to reduce adverse immunological responses. Single chain antibodies may be used for either or both of the two regions of the molecules of the invention.

Preferred embodiments will now be described by way of example and with reference to the accompanying figures.

Figure 1 illustrates the construction of plasmids pDBP1, pDBP2 and pDBP3. E = *EcoRI*, P = *PstI*, Bg = *BglII*, H = *HindIII*, B = *BamHI* and A = *AflIII*. Only the *BglII* and *AflIII* sites present in the PAI-2 encoding sequence are shown;

Figure 2 shows a DNA sequence encoding, and corresponding amino acid sequence of, PAI-2 in pDBP3;

Figure 3 (on two sheets) shows the DNA sequence of the *PRB1* promoter;

Figures 4 to 8 respectively illustrate plasmids pAYE333, pAYE334, pAYE335, pDBP5 and pDBP6;

Figure 9 illustrates the construction of plasmids pDJB117 and pDJB118;

Figure 10 illustrates the construction of plasmid pDBUP1;

Figure 11 illustrates the construction of plasmids pDBA2, pDBUA1, pDBUA2 and pDBUA3.

Figure 12 shows the DNA sequences and amino acid sequence encoded thereby, for α_1 antitrypsin in pDBUA1.

Example 1

Standard recombinant DNA procedures are as described by Sambrook et al, 1989 unless otherwise stated.

General

A plasminogen activator inhibitor 2 coding sequence (Figure 1) may be derived from EP-A-238 275. The DNA may be obtained from *E. coli* deposited as ATCC 53585 in connection with EP 238 275. This contains the plasmid pBTA438, comprising the PAI-2 sequence. The sequences encoding the uPA growth factor domain may be assembled from synthetic oligonucleotides by standard procedures.

However, we obtained a cDNA sequence for PAI-2 ourselves by analogous techniques. An expression vector was constructed in which DNA encoding amino acids 1-47 of uPA, preceded by a methionine initiation codon, directly preceded DNA encoding PAI-2 such that the two coding sequences were in frame. Expression of these sequences was under the control of the *S. cerevisiae* *PRB1* gene promoter and transcription termination was effected by the *S. cerevisiae* *ADH1* terminator.

Specific Detail

PAI-2 Coding Sequence

A lambda gt11 cDNA library constructed from mRNA isolated from 4-phorbol-12-myristate-13-acetate stimulated cells of the human monocyte-like histiocytic lymphoma cell line U937 (obtained from Clontech Laboratories Inc) was used as a source of PAI-2 cDNA. The library was screened using radioactively labelled oligonucleotide probes corresponding to the DNA sequences encoding the N-terminus (oligo 1) and C-terminal end (amino acids 400-410) (oligo 2) of the PAI-2 protein, respectively.

Oligo 1

5'-ATG GAG GAT CTT TGT GTG GCA AAC ACA CTC TTT-3'

Oligo 2

5'-GCC GAA AAA TAA AAT GCA CTT GGT TAT CTT ATG-3'

From the putative positive clones we selected one clone (lambda gt11-186) which appeared to contain the entire PAI-2 coding region. This was confirmed by sequence analysis of the DNA insert in this clone following transfer to M13mpl9 to form pDBP1 (Figure 1).

To facilitate insertion into expression vectors, restriction enzyme recognition sites were created at the 5' and 3' ends of the PAI-2 gene. A *Bgl*III site was created at the 5' end of the gene using the oligonucleotide primer

5'-TGCCACACAAAGATCTTCCATTGTTTCAATCT-3'

to create a mutation in the third position of the second codon as shown below:-

M E D L ~~C~~ V A

5'...AGATTGAAACA ATG GAG GAT CTT TGT GTG GCA...3'

3'...TCTAACTTTGT TAC CTC CTA GAA ACA CAC CGT...5'

changed to:-

M E D L C V A

5'...AGATTGAAACA ATG GAA GAT CTT TGT GTG GCA...3'

3'...TCTAACTTTGT TAC CTT CTA GAA ACA CAC GCT...5'

┌────────┐

*Bgl*III

An *Alf*II site was created at the 3' end of the gene using the oligonucleotide primer:

5'-CAGAAGCAGCACGCTTAGTCTTAAGGTGAGGAAATCTGCC-3'

to create mutations in the third position of the last codon (proline) and in the first base after the stop codon as shown below:-

G R F S S P STOP

5'...GGC AGA TTT TCC TCA CCC TAA AACTAAGCGTGCTGCTTCTG...3'

3'...CCG TCT AAA AGG AGT GGG ATT TTGATTCGCACGACGAAGAC...5'

changed to:

G R F S S P STOP

5'...GGC AGA TTT TCC TCA CCT TAA GACTAAGCGTGCTGCTTCTG...3'

3'...CCG TCT AAA AGG AGT GGA ATT CTGATTCGCACGACGAAGAC...5'

┌────────┐

*Afl*III

These two oligonucleotides were annealed to single stranded pDBP1 and then used in an *in vitro* mutagenesis procedure (Amersham plc) carried out according to the manufacturer's recommendations. A clone derived from this procedure and with the correct changes was designated pDBP2 (Figure 1).

Oligonucleotide linkers were then used to position restriction sites at either end of the gene which are suitable for insertion of the gene into an expression vector. The linker positioned at the 5' end of the gene was

Linker 1

5'-AGCTTGTCTGACGGATCCAAAAAG ATG GAA

ACAGCTGCCTAGGTTTTTC TAC CTT CTAG-5'

HindIII

BamHI

BglII

and the 3' linker was

Linker 2

5'-TTAAGTCGACAAGCTTG

CAGCTGTTTGAACCTAG-5'

AflIII

BamHI

These two linkers were ligated with the *Bgl*III-*Afl*III PAI-2 gene fragment from pDBP2 into *Hind*III + *Bam*HI digested M13mp19 to form pDBP3 (Fig. 1). The DNA sequence of PAI-2 in pDBP3 is shown in Figure 2.

PRB1 Promoter

The structural gene, *PRB1*, for the *Saccharomyces cerevisiae* vacuolar endoprotease B has been isolated (Moehle et al, 1987a) on two *prb1* complementing plasmids called MK4 and FP8. When the yeast *Saccharomyces cerevisiae* is grown on glucose in shake flask culture, very little protease B activity is detected until the cells have catabolised the glucose and are utilising the ethanol accumulated during growth (Saheki and Holzer, 1975; Jones et al, 1986). This is believed to be a consequence of a transcriptional control mechanism which represses mRNA accumulation until the glucose has been exhausted and the culture enters the diauxic plateau (Moehle et al, 1987a). Studies with protease B (*prb1*⁻) deficient mutants implicate protease B in the protein degradation that occurs when negative cells are starved of nitrogen and carbon (Wolf and Ehmann, 1979; Zubenko and Jones, 1981).

The DNA sequence of the *PRB1* gene has been reported, as has 150bp of the *PRB1* promoter (Moehle *et al*, 1987b). A more extensive DNA sequence of the *PRB1* promoter is also available as an entry in the Genbank database, release 60, accession number M18097, locus YSCPRB1, Figure 1.

The whole of the *PRB1* promoter may be used, or a smaller portion thereof, as may readily be determined. For example, the roughly 1kbp sequence extending upstream from the start codon to the *SnaB1* site is effective.

The 1.435kbp *HindIII*-*EcoRI* DNA fragment containing the protease B promoter (Figure 3) was cloned into the polylinker of the M13 bacteriophage mp18 (Yanisch-Perron *et al*, 1985), generating plasmid pAYE333 (Figure 4). Plasmid pAYE333 was linearised by partial digestion with *SnaB1* and the double standard oligonucleotide linker 3 inserted by ligation.

Linker 3

5'-GCGGCCGC-3'

3'-CGCCGGCG-5'

┌────────┐

NotI

This generates a *NotI* restriction site at the 5' end of the protease B promoter. The promoter element was further modified by site directed mutagenesis (oligonucleotide direct *in vitro* mutagenesis system-Version 2, Amersham) according to the manufacturer's instructions. Mutagenesis with the oligonucleotide

5'-CGCCAATAAAAAACAAGCTTAACCTAATTC-3'

introduces a *HindIII* restriction site close to the ATG translation initiation codon:

CGCCAATAAAAAACAAGCTTAACCTAATTCTAACAAGCAAAGATG

| | Met

| |

* *

CGCCAATAAAAAACAAGCTTAACCTAATTCTAACAAGCAAAGATG

┌ Met

HindIII

Plasmid pAAH5 (Goodey *et al*, 1987) was linearised by partially digesting with *BamHI*. The 5' protruding ends were blunt-ended with T4 DNA polymerase and ligated with the double-stranded oligonucleotide Linker 3. A recombinant plasmid

pAYE334 (Figure 5) was selected in which a *NotI* restriction site had replaced the *BamHI* site at the 3' end of the *ADHI* terminator.

The 0.8kbp *NotI-HindIII* modified protease B promoter sequence was placed upstream of the 0.45kbp *HindIII-NotI ADHI* transcription terminator on a pAT153-based plasmid (Twigg and Sherratt, 1980) to generate pAYE335 (Figure 6).

The large 6.38kbp *HindIII-BamHI* fragment from the yeast *E. coli* shuttle vector pJDB207 (Beggs, 1981) was treated with the Klenow fragment of *E. coli* DNA polymerase to create flush ends and ligated with the double stranded oligonucleotide Linker 3 to generate plasmid pDBP5 (Figure 7).

The 1.25 kbp *NotI* Protease B promoter/*ADHI* terminator cassette from plasmid pAYE335 (Figure 6) was introduced into the unique *NotI* site of plasmid pDBP5, generating pDBP6 (Figure 8).

uPA-PAI-2 fused coding region

Two oligonucleotides were synthesised using an Applied Biosystems Inc 380B oligonucleotide synthesiser and annealed to form a linker (linker 5) to encode the C-terminal portion of the uPA growth factor domain (amino acids 24-47) and the start of the PAI-2 sequence.

Linker 5

Y F S N I H W C N C P K K F G
 TCGAGTAC TTC TCC AAC ATT CAC TGG TGC AAC TGC CCA AAG AAA TTC GGA
 CATG AAG AGG TTC TAA GTG ACC ACG TTG ACG GGT TTC TTT AAG CCT

ScaI

G Q H C E I D K S M E
 GGG CAG CAC TGT GAA ATA GAT AAG TCA ATG GAA
 CCC GTC GTG ACA CTT TAT CTA TTC AGT TAC CTT CTA G

BglII

This linker was ligated with a *BglII-HindIII* fragment of pDBP3, representing the remainder of the PAI-2 sequence, into pUC18 at *SalI-HindIII* to form the plasmid pDJB117 (Figure 9).

A second linker representing the *PRB1* ATG environment, a methionine initiation codon and DNA encoding the N-terminal portion of the uPA growth domain (amino acids 1-23) was assembled by annealing the four oligonucleotides shown below:-

Linker 6

oligo 3

```

      M   S   N   E   L   H   Q   V
GATCAAGCTTAACCTAATTCTAACAAGCAAAG ATG AGC AAT GAA CTT CAT CAG GTA
TTCGAATTGGATTAAGATTGTCGTTTC TAC TCG TTA CTT GAA GTA GTC CAT

```

HindIII

oligo 6

oligo 4

```

P   S   N   C   D   C   L   N   G   G   T   C   V   S   N   K
CCA TCG AAC TGT GAC TGT CTA AAT GGA GGA ACA TGT GTG TCC AAC AAG
GGT AGC TTG ACA CTG ACA GAT TTA CCT CCT TGT ACA CAC AGG TTG TTC

```

oligo 5

┌
T
A
└

The plasmid pDJB117 was partially digested with *ScaI* and linearised DNA was isolated from an agarose gel and then digested with *BamHI*. This DNA was ligated with linker 6 to form pDJB118 (Figure 9).

The *HindIII* fragment from pDJB118 (Figure 9) containing the uPA-PAI-2 coding sequence was then introduced into the expression plasmid pDBP6 to form pDBUP1 (Figure 10). Plasmid pDBUP1 contains a *PRB1* promoter fragment to control transcription of the uPA-PAI-2 sequence and the *ADH1* transcription terminator. It also contains sequences of the bacterial plasmid pAT153 (Twigg and Sherratt, 1980), the *leu2d* gene for selection of transformants and part of the 2 μ m plasmid to provide replication function in *S. cerevisiae*. The plasmid was introduced into a suitable *S. cerevisiae* strain wherein it effected production of the hybrid protein as a soluble intracellular protein which was recognised by anti-PAI-2 and anti-uPA antibodies in Western blotting experiments.

The protein was purified from cell lysates by copper chelate and anion exchange chromatography and was found to inhibit uPA with similar kinetics to PAI-2 itself and to bind to U937 cells via the uPA receptor.

Example 2

A human α_1 -antitrypsin cDNA, identical in sequence to that described in the Genbank database, release 60, accession number X01683 V00496, locus HUMA1ATR was amplified by Polymerase Chain Reaction using a Perkin Elmer Cetus DNA thermal cycler according to the manufacturer's instructions. The DNA sequence of the two primary oligonucleotides were:

5' Oligonucleotide

5'-GAGGATCCCCAGGGAGATGCTGCCCAGAAG-3'

3' Oligonucleotide

5'-GGGGAAGCTTTTATTTTGGGTGGGATTCACCACTTTTCC-3'

Upon amplification both the 5' and 3' termini of the α_1 -antitrypsin sequence became modified as follows:

5' Terminus

original

G GTC CCT GTC TCC CTG GCT GAG GAT CCC CAG GGA GAT GCT GCC CAG
 V P V S L A E D P Q G D A A Q

*Bam*HI

AAG

K

modified

GAG GAT CCC CAG GGA GAT GCT GCC CAG AAG
 E D P Q G D A A Q K

*Bam*HI3' Terminus

original GGA AAA GTG GTG AAT CCC ACC CAA AAA TAA CTGCCTCTCG
 G K V V N P T Q K *

modified GGA AAA GTG GTG AAT CCC ACC CAA AAA TAA AAGCTTCCCC
 G K V V N P T Q K * ┌───┐
HindIII

These modifications remove the 23 amino acid signal sequence and introduce a *HindIII* restriction site at the 3' end of the cDNA.

The 1.22kbp modified cDNA was purified, digested with *HindIII* and *BamHI* inserted and cloned into the *HindIII*-*BamHI* sites of M13mpl9 (Yanisch-Perron et al. (1985) Gene 33, 103-119) generating pDBA1 (Figure 11). The integrity of human α_1 -antitrypsin was confirmed by dideoxynucleotide sequencing.

A sequence encoding α_1 -antitrypsin Pittsburgh (α_1 AT-P) (Owen *et al*, 1983) was created using oligonucleotide-directed mutagenesis of pDBA1 using the oligonucleotide shown below

5'-GAGGCCATACCCAGGTCTATCCCC-3'

This resulted in a change in the codon for methionine 358 such that it coded instead for an arginine ie ATG -> AGG. This plasmid is pDBA2 (Fig 11).

Two oligonucleotides were synthesised and then annealed to form a linker (Linker 7) to encode the C-terminal portion of the uPA growth factor domain (amino acids 24-47) and the start of the α_1 AT-P sequence.

Linker 7

Y F S N I H W C N C P K K F
 AGTAC TTC TCC AAC ATT CAC TGG TGC AAC TGC CCA AAG AAA TTC
 CATGTCATG AAG AGG TTG TAA GTG ACC ACG TTG ACG GGT TTC TTT AAG

┌───┐
ScaI

G G Q H C E I D K S E
 GGA GGG CAG CAC TGT GAA ATA GAT AAG TCA GAG
 CCT CCC GTC GTG ACA CTT TAT CTA TTC AGT CTCCTAG

┌───┐
BamHI

This linker was ligated with *KpnI*-*BamHI* digested pDBPA2 to form pDBUA1 (Fig 11).

A second linker representing the *PRB1* ATG environment, a methionine initiation codon and DNA encoding the N-terminal portion of the uPA growth domain (amino acids 1-23) was assembled by annealing the four oligonucleotides shown below:-

Linker 8

oligo 7

M S N E L H Q V
 AATTAAGCTTAACCTAATTCTAACAAGCAAAG ATG AGC AAT GAA CTT CAT CAG GTA
 TTCGAATTGGATTAAGATTGTTTCGTTTC TAC TCG TTA CTT GAA GTA GTC CAT

HindIII

oligo 6

oligo 4

P S N C D C L N G G T C V S N K
 CCA TCG AAC TGT GAC TGT CTA AAT GGA GGA ACA TGT GTG TCC AAC AAG
 GGT AGC TTG ACA CTG ACA GAT TTA CCT CCT TGT ACA CAC AGG TTG TTC

oligo⁵

┌

T

A

└

This plasmid pDBUA1 was digested with *ScaI* and *EcoRI* and then ligated with linker 8 to form pDBUA2 (Fig 11). The *HindIII* fragment of pDBUA2 was then introduced into the expression plasmid pDBP6 to form pDBUA3 (Fig 11). This plasmid was then introduced into a suitable *S. cerevisiae* strain wherein it effected production of the hybrid protein which was recognised by anti- α_1 AT and anti-uPA antibodies in Western blotting experiments.

REFERENCES

Appella, E. et al (1987). *J. Biol. Chem.* 262, 4437-4440.

Beggs, J.D. (1978). *Nature* 275, 104-109

Beggs, J.D. (1981) *Molecular Genetics in Yeast*, Alfred Benzon Symposium 16, 383-395

Danø, K. et al (1985). *Adv. Cancer Res.* 44, 139-266

Goodey, A.R. et al (1987) In *Yeast Biotechnology*, 401-429, Edited by Berry, D.R., Russell, I. and Stewart, G.G. Published by Allen and Unwin

Jones et al (1986) *UCLA Symp. Mol. Cell Biol. New Ser.* 33. 505-518

Kirchheimer, J.C. and Remold, H.G. (1989a). *Blood* 74, 1396-1402

Kirchheimer, J.C. and Remold, H.G. (1989b). *J. Immunol.* 143, 2634-2639

Kruithof, E.K.O. et al (1986). *J. Biol. Chem.* 261, 11207-11213

Miles, L.A. and Plow, E.F. (1988). *Fibrinolysis* 2, 61-71

Miles, L.A. et al (1988) *J. Biol. Chem.* 263, 11928-11934

Moehle et al (1987a) *Genetics* 115, 255-263

Moehle et al (1987b) *Mol. Cell. Biol.* 7, 4390-4399

Neuberger, M.S. et al (1988) *8th International Biotechnology Symposium Part 2*, 792-799

Norrande, J. et al (1983) *Gene* 26, 101-106

Ossowski, L. (1988). *Cell* 52, 321-328

Ossowski, L. and Reich, E. (1983). *Cell* 35, 611-619

O'Sullivan et al (1979) *Anal. Biochem.* 100, 100-108

Owen et al (1983) *N. Engl. J. Med.* 309, 694-698

Pöllänen, J. et al (1990). *Proc. Natl. Acad. Sci. USA* 87, 2230-2234

Reich, E. et al (1987). *Cancer Res.* 48, 3307-3312

Saheki, T. & Holzer, H. (1975) *Biochem. Biophys. Acta* 384, 203-214

Sambrook, J. et al (1989). *Molecular cloning : a laboratory manual, 2nd edition*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.

Tan, L.K. and Morrison, S.L. (1988) *Adv. Drug Deliv. Rev.* 2, 129-142

Twigg, A.J. and Sherratt, D. (1980). *Nature* 283, 216-218

Vassalli, J.D. et al (1985). *J. Cell Biol.* 100, 86-92

Williams, G. (1988) *Tibtech* 6, 36-42

Wolf, D. and Ehmann, C. (1979) *Eur. J. Biochem.* 98, 375-384

Wun, T.C. and Reich, E. (1987). *J. Biol. Chem.* 262, 2646-3653

Yanisch-Perron et al (1985) *Gene* 33, 103-119

Zola, H. (1988) "*Monoclonal Antibodies: a Manual of Techniques*", C.R.C. Press

Zubenko, G. and Jones, E. (1981) *Genetics* 97, 45-64

CLAIMS

1. A molecule comprising a first region which binds to a tumour cell and a second region which inhibits a tumour-associated protease.
2. A molecule according to Claim 1 wherein the first region binds to a receptor for the protease and the second region inhibits the action of the protease.
3. A molecule according to Claim 2 wherein the first region binds to the receptor in such a way as to block binding thereto by the protease.
4. A molecule according to Claim 3 wherein the first region comprises a receptor-binding portion of the protease or a receptor-binding variant thereof.
5. A molecule according to any one of the preceding claims wherein the protease is uPA and the receptor is the uPA receptor (uPAR).
6. A molecule according to Claim 5 wherein the first region comprises a peptide corresponding to amino acids 20-30 of uPA.

7. A molecule according to Claim 6 wherein the first region comprises a peptide corresponding to amino acids 12 to 32 of uPA.
8. A molecule according to Claim 7 wherein the first region comprises a peptide corresponding to amino acids 1 to 47 of uPA.
9. A molecule according to Claim 7 or 8 wherein the first region comprises a non-plasminogen-activating mutant of uPA or pro-uPA.
10. A molecule according to any one of Claims 6 to 9 wherein the second region is PAI-2 or a uPA-inhibiting variant or fragment thereof.
11. A molecule according to any one of Claims 6 to 9 wherein the second region is α_1 -antitrypsin (Pittsburgh) or a uPA-inhibiting variant or fragment thereof.
12. A molecule according to any one of the preceding claims comprising a polypeptide consisting of the first and second regions and, optionally, an intervening amino acid sequence combined to form a single amino acid sequence.

13. A nucleotide sequence encoding a polypeptide as defined in Claim 12.
14. A process of producing a molecule according to any one of Claims 1 to 12 comprising (a) preparing the said first and second regions and joining them together or (b) preparing the first and second regions and, optionally, an intervening amino acid sequence, as a single polypeptide by expressing a nucleotide sequence encoding the polypeptide in a suitable host cell transformed with the nucleotide sequence.
15. A process according to Claim 14 (b) wherein the host cell is a *Saccharomyces cerevisiae* cell.
16. A method of combatting neoplasms comprising administering to a patient a molecule according to any one of Claims 1 to 12.
17. A compound which binds specifically to uPAR and to PAI-2.
18. A compound according to Claim 17 wherein the compound is a bispecific antibody.

19. A pharmaceutical composition comprising a molecule according to any one of Claims 1 to 12 or a compound according to Claim 17 or 18.